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Abstract
Background: Following the recent outbreak of the new coronavirus pandemic (Covid-19), the rapid determination
of the structure of the homo-trimeric spike glycoprotein has prompted the study reported here. The aims were to
identify potential “druggable” binding pockets in the protein and, if located, to virtual screen pharmaceutical agents
currently in use for predicted affinity to these pockets which might be useful to restrict, reduce, or inhibit the
infectivity of the virion.
Results: Our analyses of this structure have revealed a key potentially druggable pocket where it might be viable to
bind pharmaceutical agents to inhibit its ability to infect human cells. This pocket is found at the inter-chain
interface that exists between two domains prior to the virion binding to human Angiotensin Converting Enzyme 2
(ACE2) protein. One of these domains is the highly mobile receptor binding domain, which must move into
position to interact with ACE2, which is an essential feature for viral entry to the host cell. Virtual screening with a
library of purchasable drug molecules has identified pharmaceuticals currently in use as prescription and over the
counter medications that, in silico, readily bind into this pocket.
Conclusions: This study highlights possible drugs already in use as pharmaceuticals that may act as agents to
interfere with the movements of the domains within this protein essential for the infectivity processes and hence
might slow, or even halt, the infection of host cells by this new coronavirus. As these are existing pharmaceuticals
already approved for use in humans, this knowledge could accelerate their roll-out, through repurposing, for
affected individuals and help guide the efforts of other researchers in finding effective treatments for the disease.
Background
Coronaviruses are a family of envelope viruses which are
hosted primarily by mammals and by birds. Their gen-
eral structure comprises of a single-stranded positive
sense RNA genome which creates four viral proteins, the
S (spike), N (nucleocapsid), M (membrane) and E (enve-
lope) proteins. Each has at least one key role: M and E
make up the primary protein components of the viral
envelope defining its shape and having a major role in
virus propagation, respectively. N is involved in stabilis-
ing the nucleocapsid binding directly to the RNA viral
material. The spike protein (S), is pivotal to viral infec-
tion as it is this that binds to receptors on the host cells
enabling subsequent fusion between the host and viral
membranes such that the interior RNA material can
then invade the host cell [1]. The S protein is comprised
of three identical polypeptide subunits arranged as a tri-
mer structure. It is this protein that gives the virus its
name as the end of the spike has the appearance of a
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small “crown” in shape. In this end region is a mobile
domain which moves from an inaccessible (down) state
to an accessible (up) state which makes it available for
interaction with Angiotensin Converting Enzyme 2
(ACE2), the transmembrane protein through which cor-
onavirus infection usually proceeds. It is the spike pro-
tein therefore, that is critical for infectivity and in this
regard it can be considered as the optimal target for vac-
cine and drug intervention, being the most prominent
on the surface of the virion.
In recent years these types of viruses have posed a
major threat due to their ability to cross the species bar-
rier, causing infection in the human population from a
virus innately from another source, mammal or bird.
Such cross-species events have resulted in Severe Acute
Respiratory Syndrome (SARS) [2] and Middle Eastern
Respiratory Syndrome (MERS) [3] which arose from bats
and then jumped to humans from civet and camel, re-
spectively, as intermediaries [4]. Such viruses that arise
in this way within the human population are potentially
very problematic in that we have no innate antibodies to
these virions and so there is always the possibility for se-
vere illness and death to occur as a result. A new cross-
species event has recently arisen in Wuhan City in
China, now termed Covid-19. The source is still being
debated, although it is likely this virus again originated
in bats and then crossed to humans probably again using
a mammalian intermediary.
The spike (S) protein from the SARS and MERS coro-
naviruses have been studied in detail and a number of
X-ray and cryo-electron microscopy (Cryo-EM) struc-
tures have been produced. Gaining detailed information
about these structures offers ways both of understanding
how the spike protein is used to infect host cells, and of
combating this infectivity. To date, two structural
models of this new coronavirus spike protein have been
produced, one [5] developed using C-I-Tasser [6], the
other [7] produced by Swiss Modeller [8] using as tem-
plates homologous structures from the SARS and MERS
spike proteins. Both models were used for evaluating the
possibility of its binding to ACE2, and Zhang et al. [5]
also dispelled suggestions of the presence of novel se-
quence inclusions in this protein.
Of key importance here, is the recently reported Cryo-
EM structure, solved to 3.5 Å resolution, of the spike
protein of Covid-19 [9] and the coordinates for this
structure are available under the Protein Data Bank
(PDB) code 6VSB; it is this structure that prompted the
investigations reported here to look for sites where it
might be possible to bind drugs. The structure here is
interesting as one subunit chain (A) is in the “up” ac-
cessible state, while the other two (B and C) are in the
“down” inaccessible state. The structure is shown in
Fig. 1 where the differences in conformation of the up
and down states are also shown. Figure 1b shows chain
A in the up state, whilst Fig. 1c shows the same view of
Fig. 1 a The structure of the Spike (S) protein from Covid-19 (PDB code 6VSB) showing its three subunit conformation. In red is chain A in the
“up” position, and chains B and C (blue and green respectively) are in the “down” position (see text for specific details). b Chain A in the up
position and c chain B in the same orientation as A, in the down position. These are coloured according to the structural differences between
them where red indicates the most significant of these differences, using 2StrucCompare [10]. Structure coloured grey only exists in chain B
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chain B but in the down state; the mobile domain is
coloured red in both cases, while structure that is in
dark grey only exists in the one chain, B in this case.
The protein retains its three fold symmetry over all re-
gions of its structure that do not interact with this mo-
bile domain. The aims were to see if pharmaceutical
products currently available and approved for human
use might be able to bind to the spike protein with the
chance that this might disrupt, stall, or even prevent, the
infection process. In order to infect, the spike protein
has to be exposed and then become accessible within
the host so it can contact the receptors on the host cell.
If infectivity were able to be slowed down because of dis-
ruption of the process, this would leave the spike protein
still exposed but in the inaccessible state and this would
enable the host to register the virion as being foreign
and so antibodies would be raised against it.
Results
Pocket identification
Results from the DoGSiteScorer server [11] identified a
total of 106 possible pockets within the Cryo-EM struc-
ture, with druggability scores ranging from 0.125 to
0.849 over a scoring range between 0 and 1, where 1
would be a perfect druggable site. Of these 106 possible
sites, 79 had a druggability score less than 0.7, and a fur-
ther 7 did not have a three-fold symmetry where it
should be expected, leaving 20 remaining sites. Remov-
ing pockets with a small overall volume (less than 500
Å3) as these were considered as unlikely to be success-
fully druggable [11], left 12 potential candidate pockets.
Analysis of these revealed an ~ 800 Å3 pocket with a
high druggability score of 0.79 which was in the 90th
percentile of those identified (Table 1 and Fig. 2), and its
location, between the mobile domain (in the down pos-
ition) of one subunit and a second subunit, suggested it
could be of potential interest regarding infectivity. Com-
parison between the residues of Covid-19 lining this
pocket and the matched SARS spike protein residues is
given in Fig. 3. Figure 4 shows the structural compari-
sons between chain A and B in the up and down states
with selected pocket residues identified to highlight the
positional changes.
Docking methods
The results from the three methods, Autodock vina [12],
Smina [13] and Ledock [14], were used to generate a list
of 4358 poses of commercially-available drugs capable of
binding into this Covid-19 spike protein pocket. None of
the pharmaceutical agents that were successfully docked
into the site displayed any steric hindrance within the
site and all of these had favourable empirically calculated
binding energies.
Analysis of the compound rankings
From the extensive spreadsheet of data, obtained from
the results of the Autodock vina, Smina and Ledock
methods, together with related information associated
with the drugs within the list (supplied as Supplemen-
tary Information), analyses were undertaken to establish
the presence of any correlations between, or statistical
significance within these results to aid further investiga-
tion. Correlations were obtained between various prop-
erties, looking for the differences/similarities between
them over the whole data set of results. Specifically, the
chemical and geometrical properties of the top 150 con-
formers, as ranked by ComboPC score, were compared
against the full dataset to see if any pattern emerged
concerning the top performing compounds. To assess
the significance of any difference found, a t-test was
employed and a ratio of the top 150 set average versus
the whole set average was obtained to assess the direc-
tion and magnitude of any difference.
Structure families
Table 2 lists the top 100 drug poses ordered by the
Combo percentile score. In this table 14 drugs are ac-
tively used for treatment and one further drug is
highlighted, as it might be available, which is used in the
treatment of various pulmonary diseases. These 15 mol-
ecules are shown in their poses binding into the pocket
in Fig. 5. Six of these are shown in Fig. 6 as selected ex-
amples of how these drugs interact with the lining
pocket residues. The figures are using the Ledock poses
in both cases.
Table 1 Residues lining the druggable pocket identified from
the DoGSiteScorer server
Chain B Residues Chain C Residues
Trp 353 Val 130
Arg 355 Thr 167
Lys 356 Phe 168
Arg 357 Asp 198
Tyr 396 Gly 199
Pro 426 Tyr 200
Asp 428 Pro 230
Phe 429 Ile 231
Thr 430 Gly 232
Phe 464 Ile 233
Glu 465
Arg 466
Ser 514
Phe 515
Glu 516
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Discussion
Our criteria for pursuing a pocket site were that the
druggability score should be high, that in the parts of
the protein where a three-fold symmetry should be
present, the same pocket should be found in each of the
subunits, that the site was of a likely suitable volume
[11], and that, if possible, the site had a high interest re-
garding either structure or function within the S protein.
The pocket identified in this study is of particular inter-
est as it is located at an interface between two chains, B
and C, of the protein and is not present between the
comparable residues in A and B or A and C. This is be-
cause chains B and C have their mobile domains in the
down position while chain A has its mobile domain in
the up position. The pocket is between two domains,
one flanking region in chain C of the protein (between
residues 1 and 290) and the other, the underside of the
mobile domain in chain B (Fig. 2). The comparison of
the pocket residues of Covid-19 and the matched SARS
spike protein residues (Fig. 3) shows a very high degree
of conservation between them, adding weight to the sug-
gestion they might be important regarding the function
of the protein. The domain in chain B is the region be-
tween residues around 335 and 526 in the Covid-19
spike protein structure, but in chain A, this same do-
main region has hinged away losing all contacts between
residues 328 and 530 (in beta strands N- and C-terminal
to the domain, respectively) as this domain is in the “up”
position. In related spike proteins like that from human
SARS-CoV (PDB code: 6ACK), when this domain is in
the up position it interacts with ACE2 facilitating entry
to the cell [16]. The movement of this domain, therefore,
appears to be required for ACE2 interaction, as in the
SARS-CoV structure an ACE2 is present and bound to
the spike protein. Critically, in the Covid-19 Cryo-EM
spike protein structure, when in the up position (and
when no ACE2 protein is present) then residues 460 to
473 in chain A are unobserved in the structure; they are
too flexible to be detectable (grey coloured structure in
Fig. 4b), whereas the equivalent residues are present in
the SARS-CoV structure with the ACE2 bound. This im-
plies they are flexible when there is no contact with the
ACE2 protein, only being stabilised in this up position
once contact has been established. However, residues
464 to 466 are structured and visible in the Covid-19
Cryo-EM B chain and form part of the side of the drug-
gable pocket (Table 1 and Fig. 4) because this chain is in
the down position. If the inter-chain interactions within
and around this pocket formed between the two do-
mains could be stabilised by the binding in of an appro-
priate drug molecule, it might prevent the domain from
moving to the up position and this could be crucial in
preventing or hindering the infectivity of the virus. The
location of this pocket near such a functionally import-
ant domain, and its high predicted druggability score
were the reasons behind this site being chosen for the
virtual screening studies.
The averaged pairwise root mean square deviation
(avRMSD) calculations between each of the docking
methods were used as a guide to the quality of each drug
pose being in a well-established position within the
druggable pocket. A small RMSD value indicated that
each method had placed the specific drug pose into a
similar position within the pocket. In vina for example,
Fig. 2 The key pocket proposed to exist in the Cro-EM spike protein structure from Covid-19 from the results of the DoGSiteScorer server. The
site is adjacent to where major movements occur when the virus changes conformation on encountering the host cell receptor, preparing it for
infection. a. Depicts the residues lining the pocket, name and sequence number, along the “axis” of the pocket. b. 90O rotation about the viewed
vertical axis from the view in A perpendicular to the “axis” of the pocket. This view is the one used to show the chosen poses in Fig. 5
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due to the non-deterministic nature of the docking algo-
rithm [12], both it and Smina [13] use a random seed
approach to initiate the search process. The results of
the poses from all three methods would ideally produce
“comparable” but not “identical” results. For all three
methods the poses obtained retain information of rota-
mer space, and overall structural space, which can be
employed to find good candidates for fitting the pocket,
but from slightly different start positions. So it would be
expected and anticipated that, for a given drug molecule,
good poses would be comparable, but not the same,
from each of the methods used, which would be
reflected in small and similar RMSD pairwise values be-
ing obtained. However, given that the scoring of the two
methods, vina and Smina, was “expected” to be different,
but in fact proved to be highly correlated in their results,
we removed the Smina scoring from the overall
ComboPC equation as we did not want to bias in favour
of these two methods over all three.
For the top 150 poses ranked by ComboPC the number of
hydrogen bond acceptors was found to be higher than ex-
pected (1.16, p < 0.001). The number of rings/heterocycles
per compound was also significantly higher (1.29, p < 0.001).
Compounds were also much more likely to contain halogen
atoms (1.74, p < 0.001), particularly fluorine atoms (2.16, p <
0.001). Compounds with SO2 groups were also over-
represented (2.97, p < 0.001), as exemplified by Ladarixin,
Diflumidone and Quinethazone. Moieties of this kind are
capable of many electrostatic interactions which need not be
associated only with hydrogen-bonding. Given the statistical
significance associated with the data above it appears that the
properties of the pocket, its shape and lining residue com-
position, have generated a focused list of drugs with notable
component properties of their own.
Fig. 3 Sequence homology between the residues of the Covid-19 and SARS spike proteins highlighting those residues lining the pocket in the
Covid-19 structure. Those residues that are identical are in white lettering on black background (20 of 25 and indicated with an asterisk), whilst
the remaining that are conservatively replaced (4 of 25 indicated by a colon or full stop) are in bold black lettering on a grey background
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In the top 100 drug poses, of interest there are 20 anti-
inflammatory drugs of which 8 are members of the “pro-
fen” family, derivatives containing the 2-arylpropionic acid
moiety. Many of the highlighted drugs in Table 2 could be
capable of successfully binding into this pocket and hence
alter the infectivity profile. Clearly, these would need to be
examined experimentally because at such a sensitive site
in the spike protein there is a possibility of promoting the
mobile domain into the up, infective conformation. How-
ever, with the fact that these drugs interact with the resi-
dues lining this pocket they might strengthen the
interaction forces in this region and prevent the mobile
domain from moving.
Conclusions
This study provides a suggested list of pharmaceutical agents,
identifying some of them as being from related structure
families, that are available on the market and have been sanc-
tioned for use in humans that have been shown to be capable
of binding into a druggable pocket in the spike protein of
Covid-19. It must be stated that whether they do or do not
actually bind in cannot be ratified here, that would have to
be determined experimentally. Some might even bind into
the site and increase infectivity as a result. However, the aims
of this study were to present and show that the members of
this list might have the capacity to bind in, thereby providing
open suggestions to experimentalists to establish whether
many, some, or few, of these agents do actually bind into the
spike protein. Equally, it is not possible to state whether these
drugs would be in any way efficacious towards suppressing
the infectivity of Covid-19 because that is not the remit of
this work. Again, that would be for those in the field to es-
tablish whether the listed drugs show any effect on reducing
virus titre levels, thereby indicating that they are indeed inter-
fering with the infectivity of the virion. The primary aim has
been to show that pharmaceutical agents already available
and approved might be usable as drugs to interfere with the
process of infection, thereby providing time for the host gen-
eration of antibodies to combat this latest of cross-species
coronavirus events.
Methods
Pocket identification
We utilised the Cryo-EM spike protein structure (PDB
code: 6VSB), as a source for our studies to locate the
presence of “druggable” pockets where small molecules
Fig. 4 Images showing the differences between paired C-alpha residues from chain A and chain B of the spike protein coloured according to
their extent of difference using 2StrucCompare [10]. Residues coloured in red indicate differences in paired positions greater than 5 Å from each
other between the two chains. a. Shows the shape and position of chain A in the “up” position. b. Shows the same orientation for chain B in the
“down” position. Some residues are labelled to indicate approximately where the pocket residues are in the two positions of these chains, and in
B three of these residues lie on the strand coloured dark grey indicating that this is not seen in chain A
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Table 2 A list of the top 100 poses of drugs ranked according to their Combo percentile score. The table consists of the Drug
name, Pharmaceutical Role, Ledock percentile score (LedockPC), Autodock vina percentile score (VinaPC), avRMSD percentile score
(RMSDPC) and overall Combo percentile score (ComboPC). Those structures indicated in bold have poses in Fig. 6. All except
Talniflumate are active pharmaceuticals, while this compound can still be active, and is highlighted because of its drug action
Drug name Pharmaceutical Rolec LedockPC VinaPC RMSDPC ComboPC
Irolapridea Antidepressant 0.001 0.004 0.053 0.02775
Pirifibrate Antilipidemic 0.065 0.031 0.015 0.0315
Etoloxaminea Antihistamine 0.054 0.101 0.008 0.04275
Timoprazolea Proton pump inhibitor 0.04 0.129 0.008 0.04625
Timoprazolea Proton pump inhibitor 0.048 0.129 0.005 0.04675
Benfluorexa Withdrawn 0.02 0.004 0.084 0.048
Vorozolea Breast cancer 0.044 0.045 0.054 0.04925
Nicotredolea Anti-inflammatory, analgesic 0.056 0.045 0.056 0.05325
Noliniuma Antispasmodic 0.046 0.031 0.069 0.05375
Talniflumatea Cystic fibrosis, COPD, asthma 0.021 0.012 0.095 0.05575
Velipariba Anti-cancer 0.07 0.024 0.066 0.0565
Timoprazolea Proton pump inhibitor 0.018 0.061 0.078 0.05875
Oxifungina Antifungal 0.043 0.08 0.057 0.05925
Fenfluthrina Insecticide 0.098 0.045 0.054 0.06275
Piketoprofenb Topical anti-inflammatory cream 0.101 0.005 0.075 0.064
Nafazatroma Antithrombotic 0.134 0.031 0.054 0.06825
Irolapridea Antidepressant 0.004 0.08 0.096 0.069
Etacepridea Neuroleptic, antiemetic 0.019 0.158 0.05 0.06925
Timoprazolea Proton pump inhibitor 0.021 0.061 0.098 0.0695
Irolapridea Antidepressant 0.002 0.08 0.1 0.0705
Cinacalcet Hyperparathyroidism 0.169 0.001 0.058 0.0715
Mitoflaxonea Antitumor 0.138 0.031 0.06 0.07225
Bendazol Vasodilator (Russia) 0.225 0.045 0.01 0.0725
Phenyltoloxamine Antihistamine 0.096 0.194 0.002 0.0735
Eprovafena Anti-inflammatory 0.067 0.129 0.052 0.075
Irolapridea Antidepressant 0.055 0.158 0.046 0.07625
Losmiprofena Anti-inflammatory, analgesic 0.134 0.158 0.008 0.077
Benfluorexa Withdrawn 0.008 0.004 0.151 0.0785
Rolodinea Muscle relaxant 0.079 0.08 0.079 0.07925
Dextrofeminea Antispasmodic 0.184 0.061 0.04 0.08125
Fenfluthrina Insecticide 0.109 0.045 0.087 0.082
Triprolidine Coughs, upper respiratory 0.026 0.101 0.103 0.08325
Losmiprofena Anti-inflammatory, analgesic 0.141 0.129 0.034 0.0845
Rolodinea Muscle relaxant 0.002 0.129 0.105 0.08525
Triafungina Antifungal 0.281 0.024 0.025 0.08875
Losmiprofena Anti-inflammatory, analgesic 0.134 0.158 0.033 0.0895
Piketoprofenb Topical anti-inflammatory cream 0.053 0.001 0.154 0.0905
Chlormidazolea Antifungal 0.221 0.101 0.027 0.094
Domoxina Antithrombotic 0.109 0.194 0.038 0.09475
Noliniuma Antispasmodic 0.052 0.031 0.148 0.09475
Timoprazolea Proton pump inhibitor 0.03 0.268 0.046 0.0975
Diflumidonea Anti-inflammatory 0.043 0.016 0.167 0.09825
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Table 2 A list of the top 100 poses of drugs ranked according to their Combo percentile score. The table consists of the Drug
name, Pharmaceutical Role, Ledock percentile score (LedockPC), Autodock vina percentile score (VinaPC), avRMSD percentile score
(RMSDPC) and overall Combo percentile score (ComboPC). Those structures indicated in bold have poses in Fig. 6. All except
Talniflumate are active pharmaceuticals, while this compound can still be active, and is highlighted because of its drug action
(Continued)
Drug name Pharmaceutical Rolec LedockPC VinaPC RMSDPC ComboPC
Pranosala Analgesic, anti-inflammatory 0.065 0.194 0.068 0.09875
Tolpentamidea Hypoglycemia 0.052 0.061 0.142 0.09925
Nafazatroma Antithrombotic 0.243 0.031 0.062 0.0995
Benfluorexa Withdrawn 0.079 0.008 0.156 0.09975
Risarestata Cornea eye treatment 0.035 0.229 0.07 0.101
Nafimidonea Anticonvulsant 0.165 0.031 0.11 0.104
Butanixina Analgesic, anti-inflammatory 0.081 0.08 0.128 0.10425
Chlormidazolea Antifungal 0.225 0.101 0.048 0.1055
Vorozolea Breast cancer 0.056 0.045 0.161 0.10575
Irolapridea Antidepressant 0.003 0.004 0.209 0.10625
Colfenamatea Antipyretic, anti-inflammatory 0.009 0.016 0.207 0.10975
Diprofenea Antispasmodic 0.101 0.158 0.09 0.10975
Alverine IBS 0.233 0.101 0.053 0.11
Fendilinea Anti anginal 0.259 0.158 0.014 0.11125
Benproperine Anti-cough 0.031 0.045 0.185 0.1115
Nicotredolea Anti-inflammatory, analgesic 0.034 0.045 0.184 0.11175
Tiaprofenic-acid Anti-inflammatory 0.269 0.158 0.01 0.11175
Tiaprofenic-acid Anti-inflammatory 0.269 0.129 0.025 0.112
Diphenana Anti-worm 0.269 0.061 0.059 0.112
Enfenamic-acida Topical anti-inflammatory 0.342 0.101 0.004 0.11275
Budralazine Vasodilator (Japan) 0.134 0.313 0.002 0.11275
Picobenzidea Neuroleptic 0.295 0.08 0.04 0.11375
Zomepiraca Withdrawn 0.162 0.158 0.068 0.114
Cinchophena Withdrawn 0.29 0.129 0.019 0.11425
Noliniuma Antispasmodic 0.087 0.08 0.146 0.11475
Pribecainea Local anesthetic 0.221 0.194 0.022 0.11475
Tepirindolea Experimental 0.138 0.024 0.149 0.115
Etoloxaminea Antihistamine 0.169 0.101 0.095 0.115
Budralazine Vasodilator (Japan) 0.144 0.313 0.002 0.11525
Triafungina Antifungal 0.403 0.024 0.017 0.11525
Nafazatroma Antithrombotic 0.176 0.045 0.121 0.11575
Triflocina Diuretic 0.285 0.158 0.011 0.11625
Tolonidinea Antihypertensive 0.233 0.194 0.024 0.11875
Isaglidolea Antidiabetic 0.144 0.194 0.069 0.119
Iquindaminea Antitussive 0.067 0.268 0.071 0.11925
Kinetina Cell division (plants) 0.037 0.362 0.039 0.11925
Cinacalcet Hyperparathyroidism 0.024 0.001 0.227 0.11975
Bencisteinea Antitussive 0.013 0.229 0.119 0.12
Salazosulfamidea Ankylosing spondylitis 0.002 0.045 0.217 0.12025
Picobenzidea Neuroleptic 0.29 0.08 0.057 0.121
Triflocina Diuretic 0.239 0.061 0.092 0.121
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could bind. The protein atomic coordinates were
uploaded to the DoGSiteScorer server [11] to identify
potential pockets within the structure. The server pro-
vides a druggability score that ranges from 0 to 1, 1 be-
ing the most druggable.
Docking methods
Three approaches to docking the pharmaceutical agents
into the identified druggable pocket in the Covid-19
spike protein were employed to act to corroborate the
output produced. These were Autodock vina [12], Smina
[13] and Ledock [14] . The centre position of the pocket
was calculated and a search grid space, defined by those
coordinates ±12 Å in the x, y and z coordinate directions
from that centre, was created and supplied to each of
the docking methods. By default in each of the packages
used, the drugs were free to explore their rotamer space
to optimise their binding into the pocket. However,
whilst it is customary to allow side chain flexibility in
the residues lining the pocket when undertaking in silico
docking studies, given that the resolution of the struc-
ture used here was only 3.5 Å, no flexible side chains
were defined.
The number of poses considered by all three methods
used was left as default because this was thought to be
optimal for this study. For Ledock, a maximum of 20
docking poses was returned per conformer, with an add-
itional pose root mean square deviation (RMSD) cutoff
of 1.0 Å applied to reduce redundancy of returned poses.
For Autodock vina and Smina, a maximum of 9 poses
with a maximum energy range of 3 kcal/mol between
best and worst were returned.
A 1049-member library of compounds was derived
from the Drugs-lib dataset available from the virtual
screening webserver MTIOpenScreen [17] from an ini-
tial study we undertook on the S protein model from I-
Tasser. This dataset consists of approved drugs and
research chemicals refined from the “drug” subset of the
ChEMBL database [18], the “approved” subset of Drug-
Bank version 5.0.10 [19], the DrugCentral online com-
pendium [20] and the “approved” SuperDrug2 database
version 2.0 [21].
Initially Autodock vina and Ledock were the methods
of choice as these have been considered as the best non_-
commercial docking packages available [22]. However,
after pairing the poses between the two methods accord-
ing to their structural similarity when in the docking site
Table 2 A list of the top 100 poses of drugs ranked according to their Combo percentile score. The table consists of the Drug
name, Pharmaceutical Role, Ledock percentile score (LedockPC), Autodock vina percentile score (VinaPC), avRMSD percentile score
(RMSDPC) and overall Combo percentile score (ComboPC). Those structures indicated in bold have poses in Fig. 6. All except
Talniflumate are active pharmaceuticals, while this compound can still be active, and is highlighted because of its drug action
(Continued)
Drug name Pharmaceutical Rolec LedockPC VinaPC RMSDPC ComboPC
Timoprazolea Proton pump inhibitor 0.101 0.129 0.128 0.1215
Fenclofenaca Withdrawn 0.169 0.158 0.08 0.12175
Ridogrela Thrombo-embolism 0.094 0.012 0.191 0.122
Ibuprofen-piconolb Topical anti-inflammatory cream 0.217 0.045 0.114 0.1225
Tecalceta Hyperparathyroidism 0.123 0.101 0.135 0.1235
Tazadolenea Antidepressant 0.364 0.061 0.035 0.12375
Piridocainea Anaesthetic 0.081 0.229 0.094 0.1245
Velipariba Anti-cancer 0.03 0.024 0.222 0.1245
Ibuprofen-piconolb Topical anti-inflammatory cream 0.2 0.101 0.103 0.12675
Furobufena Anti-inflammatory 0.249 0.194 0.032 0.12675
Prefenamatea Anti-inflammatory 0.008 0.061 0.22 0.12725
Bakeprofena Analgesic, antipyretic 0.281 0.045 0.092 0.1275
Fenfluthrina Insecticide 0.372 0.045 0.047 0.12775
Isaglidolea Antidiabetic 0.148 0.194 0.086 0.1285
Clomacrana Withdrawn 0.007 0.061 0.224 0.129
Abacavir HIV treatment 0.003 0.268 0.124 0.12975
Oxaprozin Anti-inflammatory 0.285 0.194 0.023 0.13125
a Indicates that the drug appears to be unavailable as an active pharmaceutical agent
b Indicates active as a drug but not suitable for internal use
c Details of the pharmaceutical role of the drugs has come from information obtained from the Inxight web pages [https://drugs.ncats.io/substances]
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(as in the RMSD Calculations below) the corresponding
docking scores showed only a weak correlation (0.36,
p < 0.0001)) and so Smina, which is reported as having a
different scoring scheme from Autodock vina [13], was
used to see if this improved the correlation of the dock-
ing scoring to Ledock. In fact, the scoring correlation be-
tween Smina and Autodock vina proved to be very high
and so only Autodock vina and Ledock data were used
in the docking scoring as a result.
RMSD calculations
For a given drug, poses were obtained that fit the pocket.
To establish the best superposition of these different
poses from each method, firstly, pairwise RMSDs were
calculated using the following equation:
RMSD ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
n
Xn
i¼1
xi−yið Þ2
s
Fig. 5 Fifteen poses (using Ledock poses) from the top 100 pharmaceutical agents listed in the data ordered by ComboPC score. Fourteen of
these are actively-used pharmaceutical compounds and the last retains the potential to be active and is given because of its pharmaceutical
activity towards cystic fibrosis, chronic obstructive pulmonary disease (COPD), and asthma. These are: a. Pirifibrate b. Cinacalcet c. Bendazol d.
Phenyltoloxamine e. Triprolidine f. Alverine g. Benproperine h. and i. Tiaprofenic acid j. and k. Budralazine l. Cinacalcet m. Abacavir n. Oxaprozin
o. Talniflumate
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where xi and yi are comparable atoms from two of the
methods, and n is the number of atoms in the given
drug. The best overall superposition from the three
methods was then calculated by taking the average of
these pairwise RMSD superpositions. From these calcu-
lations, the poses from each of the methods with the
best overall superposition, and hence, highest degree of
similarity, would have the lowest average RMSD values
(avRMSD).
Overall druggability analysis and ranking
An extensive amount of data was generated tabulating the
output information from the docking packages of the
druggable compounds with their structural characteristics.
In generalised overview these correspond to the docking
output scores from each of the methods, avRMSD values
between the poses chosen for each compound, hydrogen
bonding data, and the JOELib Native descriptor set, calcu-
lated using the ChemMine webserver [23], which include
molar refractivity, polar surface area, and frequencies of
atom and selected group types among other geometric
and chemical properties. Drugs within the search group
were also classified by chemical compound class and,
where possible, by subclass through classification using
the ClassyFire webserver [24].
A compound with a pose that scored highly in the two
scoring regimes, and with good superposition agreement
between docking methods, as determined from their
avRMSD values, was considered more likely to be a
meaningful data point. As these individual terms were
on different scales, their significant feature was their
explicit “order” rather than “value”. As a result each
component, scoring value, and avRMSD, was ranked ac-
cording to their percentile position within their individ-
ual scales. This therefore ordered the results by position
rather than by value. Thus, the following combined
score, ComboPC, was created to rank the compounds
applying equal weight to the estimated docking scores
from each docking method and to the agreement be-
tween the superpositions from each of the methods, as
measured by avRMSD:
ComboPC ¼ 1
2
LedockPC þ vinaPCð Þ
2
þ RMSDPC
 
Where LedockPC is the percentile rank of the docking
score of the pose as docked by Ledock, vinaPC is the
Fig. 6 Selected Ligplot [15] diagrams from the fifteen poses in Fig. 5 (using Ledock poses). These figures indicate the interactions between the drug
(the ligand, displayed in ball and stick format) and the surrounding pocket residues. Hydrogen bonds are indicated by a dashed line between the drug
ligand atom and the atom of the residue lining the pocket which is also displayed in ball and stick in these instances. Van der Waals contacts are
indicated by “fans” of lines around each residue directed towards the drug which also have reciprocal fans directed towards each of the residues lining
the pocket with which it is interacting. The plots are for the drugs: a. Pirifibrate b. Cinacalcet c. Bendazol d. Phenyltoloxamine e. Triprolidine f. Alverine
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percentile rank of the docking score of the pose as
docked by vina, and RMSDPC is the percentile rank of
the avRMSD between the poses from each docking
method. Only the scores from Ledock and vina, but not
Smina, were chosen for inclusion in the ComboPC score
as the scores from vina and Smina were found to be
highly correlated (0.97, p < 0.001)).
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